Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study

S. Adams, S. Loi, D. Toppmeyer, D. W. Cescon, M. De Laurentiis, R. Nanda, E. P. Winer, H. Mukai, K. Tamura, A. Armstrong, M. C. Liu, H. Iwata, L. Ryvo, P. Wimberger, H. S. Rugo, A. R. Tan, L. Jia, Y. Ding, V. Karantza, P. Schmid

Research output: Contribution to journalArticle

105 Scopus citations

Fingerprint Dive into the research topics of 'Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study'. Together they form a unique fingerprint.

Medicine & Life Sciences